This past week delivered one of the more instructive earnings contrasts of the year. Taiwan Semiconductor Manufacturing Company (TSM) reported its best quarter in history and watched its stock fall. UnitedHealth Group (UNH) reported a massive beat, raised its guidance, and rallied hard. Both moves say something important about how markets are thinking about risk right now.
TSMC: A Historic Quarter the Market Didn't Want
On July 16, 2026, Taiwan Semiconductor Manufacturing Company — the foundry behind nearly every advanced AI chip on the planet — reported Q2 2026 results that were objectively stunning.
Revenue came in at $40.20 billion for the quarter, up 12.0% sequentially from $35.90 billion in Q1 2026 and up 33.7% from a year earlier. Net income hit $22.00 billion, a 77.4% jump year-over-year. Diluted earnings per ADR were $4.31, well above the $3.82 analyst consensus. Gross margin was 67.7% — above the high end of management's own guidance range. Net margin came in at 55.6%.
Beyond the headline numbers, TSMC raised its full-year 2026 revenue growth outlook from above 30% to above 40%, and increased its 2026 capital expenditure budget to between $60.00 billion and $64.00 billion — up from the previous $52.00 to $56.00 billion range. It also guided Q3 2026 revenue between $44.60 billion and $45.80 billion, implying roughly another 12% sequential jump.
And the stock fell.
As of Friday, July 18, TSM shares trade at $397.14, down 17.1% from the 52-week high of $479.00. The stock has dropped for seven consecutive sessions. The 52-week low is $223.70. Market cap is $2.06 trillion. The P/E is 33.10.
The reason isn't the fundamentals — it's the macro backdrop. A global semiconductor selloff accelerated this week as investors rotated out of AI-exposed names. Taiwan markets fell 6.5%. The Philadelphia Semiconductor Index has had its worst stretch in months. Concern about geopolitical risk in the Taiwan Strait, combined with a broader repricing of AI valuations, has weighed on every chip name regardless of underlying results.
Of 7 analysts currently tracked, 85.7% carry bullish ratings on TSM. The average price target is $505.71, representing 27.3% upside from current levels. The high target is $650.00, set by Barclays, which reiterated Overweight on July 17, 2026. DA Davidson set a $500.00 target the same day. Susquehanna raised its target to $600.00 on July 16 and maintained a Positive rating.
The disconnect between the business and the stock price is meaningful. TSMC makes the chips that run every major AI model — Nvidia's H100 and Blackwell GPUs, Apple Silicon, Qualcomm's Snapdragon. Its backlog is sold out through 2027 in advanced nodes. A 27.3% gap between current price and the analyst consensus is notable for a company that just raised its full-year outlook by 10 percentage points.
UnitedHealth Group: A Beat the Market Rewarded
On the same day TSMC reported, UnitedHealth Group (UNH) delivered a quarter that went the other direction for the stock.
For Q2 2026, UnitedHealth posted revenue of $112.03 billion and net income of $5.67 billion. GAAP diluted EPS was $6.04. Adjusted EPS was $6.38, handily beating the Wall Street consensus of around $4.90 and representing a significant improvement driven by tighter medical cost management. Q1 2026 had produced EPS of $6.90 on revenue of $111.72 billion.
Management raised full-year 2026 adjusted EPS guidance to $19.50 to $20.00 per share, up from the prior outlook of more than $18.25. The stock surged more than 7% on the day.
At Friday's price of $432.03, UNH sits just 6.4% below its 52-week high of $461.62 — meaning the market wasted little time rewarding the report. The 52-week low is $234.60. Market cap is $392.35 billion. P/E is 26.44.
The medical cost ratio — the percentage of premium revenue paid out in claims — came in better than feared, which was the key number investors had been watching since the stock's sharp decline earlier this year. UnitedHealth had faced serious questions about whether rising medical utilization would persist through 2026. The Q2 result suggested the pressure is easing.
Of 16 analysts tracked, 81.2% hold bullish ratings on UNH. The average price target is $470.56, implying 8.9% additional upside from current levels. The high target is $529.00, set by Morgan Stanley, which raised its target from $468.00 to $529.00 on July 17, 2026, maintaining Overweight. Keybanc and Oppenheimer both raised their targets to $500.00 on the same date.
Found this helpful? Share it with others.